VERTEX PHARMACEUTICALS (IRELAND) LIMITED

Alyftrek is intended for the long-term treatment of people aged 6 years and older with cystic fibrosis (CF) who have at least one drug-responsive CFTR gene mutation. It works by improving lung function and breathing.

Dosage form: tablets, film-coated

ATC: R07AX33

It is used for the treatment of people aged 12 years and older with beta-thalassemia who require regular blood transfusions, and people aged 12 years and older with sickle cell disease who experience frequent pain crises.

Dosage form: solution for infusion

ATC: B06AX05

Kaftrio is a long-term treatment for patients with cystic fibrosis (CF) who have at least one CFTR gene mutation specific to responding to the drug. It helps lung cells function better, promoting breathing and improving lung function.

Dosage form: tablets, film-coated

ATC: R07AX32

The drug is indicated for the treatment of cystic fibrosis (CF) in patients (children and adults) who have specific mutations in the CFTR gene. It works by helping abnormal proteins improve the movement of chloride through the cells.

Dosage form: tablets, film-coated

ATC: R07AX02

It is used for the long-term treatment of cystic fibrosis in patients (aged 1 year and older) who have a specific genetic mutation called F508del.

Dosage form: tablets, film-coated

ATC: R07AX30

This medicine helps the lung cells work better in some patients with cystic fibrosis (CF). It is used to improve lung function and breathing, and it may help with weight gain or getting sick less often.

Dosage form: tablets, film-coated

ATC: R07AX31